Aurora, CO Clinical Trials Report — May 2026

For Aurora residents considering participation in clinical research, May 2026 offers both urgent opportunities and exciting new avenues to contribute to medical science. Across Aurora, CO, a total of 988 clinical trials are currently recruiting participants at 316 research facilities, providing numerous ways to get involved.

Time is of the essence for those interested in specific studies, as 58 clinical trials are slated to conclude their enrollment within the next 90 days. This includes 8 trials that are actively seeking healthy volunteers, offering a chance to contribute to medical advancements before their enrollment windows close.

Impending Deadlines for Key Health Areas

Patients managing specific health conditions also face impending deadlines to join research. Trials focused on various types of cancer, neurological conditions, and rare diseases are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (3 trials)
• Advanced solid tumors (2 trials)
• Myasthenia gravis (2 trials)
• B-cell acute lymphoblastic leukemia (2 trials)
• Transgenderism (2 trials)
• Advanced NSCLC (1 trial)
• Advanced cancer (1 trial)
• Advance care planning (1 trial)
• Anger (1 trial)
• Aging (1 trial)

New Research Opportunities Emerge in May

This month, Aurora saw the opening of 17 new clinical trials, a notable increase from the 11 trials that launched in April 2026. This uptick indicates a growing research landscape in the city.

May brings several high-profile new trials to Aurora, including significant Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is initiating two notable Phase 3 studies:
  • NCT07567001: "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This trial aims for 5,610 participants to evaluate the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved or mildly reduced Ejection Fraction and excess body weight.
  • NCT07564414: "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This study involves 2,500 participants and is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes, lose weight.
• AstraZeneca is sponsoring NCT07611110: "AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)." This Phase 3 study aims for 670 participants to demonstrate the superiority of AZD2265 relative to standard of care treatments for prostate cancer.
• The Duchenne Registry is leading NCT07609394: "Duchenne Electronic Health Record Study." This study aims to collect retrospective and prospective, long-term data of 2,500 patients with dystrophinopathy (including Duchenne, Becker, and female carriers) through electronic transfer.
• The University of Colorado, Denver is sponsoring NCT07569224: "Testing the Impact of the MOHR Follow-up Support." This study, involving 1,000 participants, will evaluate the impact of different strategies to increase engagement in My Own Health Report (MOHR) and health behavior change activities.
• Stephanie Di Stasi is sponsoring NCT07584252: "The Healing and Empowerment Actions for Recovery From Trauma (HEART) Trial." This study aims for 804 participants to determine if wrap-around psychosocial support for patients who sustain moderate to severe trauma requiring orthopedic surgery intervention improves outcomes.

New trials this month are exploring a range of conditions, with the most frequent being congenital heart disease (2 trials) and obesity (2 trials). Other conditions include clonal cytopenia of undetermined significance, cognition, COPD, depression in adolescence, Down syndrome, and Duchenne muscular dystrophy. Drug trials account for the largest share of new studies, with 9 new drug trials, followed by 6 "other" types of studies, 5 behavioral studies, and 1 biological study.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 17 new trials launched this month, 1 is actively seeking healthy volunteers. Across Aurora, a total of 123 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Aurora's Leading Research Facilities

Aurora is home to some of Colorado's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Children's Hospital Colorado (163 trials)
• University of Colorado Anschutz Medical Campus (92 trials)
• University of Colorado (80 trials)
• UCHealth University of Colorado Hospital (56 trials)
• University of Colorado Hospital (48 trials)
• University of Colorado Cancer Center (38 trials)
• University of Colorado Denver (28 trials)
• Rocky Mountain Regional VA Medical Center, Aurora, CO (25 trials)
• Research Site (25 trials)
• Rocky Mountain Cancer Centers-Aurora (24 trials)

The University of Colorado system, including its Anschutz Medical Campus, hospitals, and specialized centers, clearly leads the research efforts in Aurora, offering a broad spectrum of studies across various medical fields.

Broadening Your Search: Nearby Colorado Options

While Aurora offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Colorado. Cities with active trials include:

• Denver (5 trials)
• Englewood (2 trials)
• Lone Tree (2 trials)
• Westminster (2 trials)
• Boulder (2 trials)
• Fort Collins (2 trials)
• Wheat Ridge (1 trial)
• Colorado Springs (1 trial)

Participation in clinical trials is open to a diverse range of individuals. Of the 17 new trials launched this month, 15 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 3 new trials include children, and 1 is male-only. Academic institutions continue to play a vital role in Aurora's research ecosystem, with the University of Colorado, Denver (4 trials) and University of Colorado, Boulder (1 trial) sponsoring several new studies. Industry sponsors like Novo Nordisk A/S (2 trials), Carelon Research (2 trials), and AstraZeneca (2 trials) are also driving significant research efforts.

As we move through May, Aurora's vibrant research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare.